Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam

BMC Infectious Diseases

Research Article

Anders Sönnerborg¹  Gaetano Marrone²  Vinod Diwan²  Anna Thorson²  Do Duy Cuong³  Mattias Larsson⁴  Vu Van Tam⁵  Ziad El-Khatib⁶  Nguyen Thi Kim Chuc⁷  Pham Nhat An⁷  Nicole K. Le⁸  Michele Santacatterina⁹ 

[1] Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;Division of Clinical Virology, Department of Laboratory Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden;Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden;Infectious Diseases Department, Bach Mai Hospital, Hanoi, Vietnam;Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden;Oxford University Clinical Research Unit (OUCRU), Hanoi, Vietnam;Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden;Vietnam-Sweden Uong Bi General Hospital, Quang Ninh, Vietnam;Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden;World Health Programme, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, Canada;Hanoi Medical University, Hanoi, Vietnam;Morsani College of Medicine, University of South Florida, Tampa, FL, USA;Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden;

关键词: Peer support;    Virologic failure;    Antiretroviral therapy;    HIV;    CD4 count;    Vietnam;   

DOI  :  10.1186/s12879-016-2017-x

 received in 2016-04-14, accepted in 2016-11-09,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe effect of peer support on virologic and immunologic treatment outcomes among HIVinfected patients receiving antiretroviral therapy (ART) was assessed in a cluster randomized controlled trial in Vietnam.MethodsSeventy-one clusters (communes) were randomized in intervention or control, and a total of 640 patients initiating ART were enrolled. The intervention group received peer support with weekly home-visits. Both groups received first-line ART regimens according to the National Treatment Guidelines. Viral load (VL) (ExaVir™ Load) and CD4 counts were analyzed every 6 months. The primary endpoint was virologic failure (VL >1000 copies/ml). Patients were followed up for 24 months. Intention-to-treat analysis was used. Cluster longitudinal and survival analyses were used to study time to virologic failure and CD4 trends.ResultsOf 640 patients, 71% were males, mean age 32 years, 83% started with stavudine/lamivudine/nevirapine regimen. After a mean of 20.8 months, 78% completed the study, and the median CD4 increase was 286 cells/μl. Cumulative virologic failure risk was 7.2%. There was no significant difference between intervention and control groups in risk for and time to virologic failure and in CD4 trends. Risk factors for virologic failure were ART-non-naïve status [aHR 6.9;(95% CI 3.2–14.6); p < 0.01]; baseline VL ≥100,000 copies/ml [aHR 2.3;(95% CI 1.2–4.3); p < 0.05] and incomplete adherence (self-reported missing more than one dose during 24 months) [aHR 3.1;(95% CI 1.1–8.9); p < 0.05]. Risk factors associated with slower increase of CD4 counts were: baseline VL ≥100,000 copies/ml [adj.sq.Coeff (95% CI): −0.9 (−1.5;−0.3); p < 0.01] and baseline CD4 count <100 cells/μl [adj.sq.Coeff (95% CI): −5.7 (−6.3;−5.4); p < 0.01]. Having an HIV-infected family member was also significantly associated with gain in CD4 counts [adj.sq.Coeff (95% CI): 1.3 (0.8;1.9); p < 0.01].ConclusionThere was a low virologic failure risk during the first 2 years of ART follow-up in a rural low-income setting in Vietnam. Peer support did not show any impact on virologic and immunologic outcomes after 2 years of follow up.Trial registrationNCT01433601.

【 授权许可】

CC BY   
© The Author(s). 2016